SCHEMBL3560779

SCHEMBL3560779

O=C(O)c1ccc(CCc2ccccc2NS(=O)(=O)c2ccccc2OC(F)(F)F)cc1

nearest known ligand 0.64

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SLC16A3 O15427 8/20 0.64
RXRA P19793 1/20 0.49
RXRB P28702 1/20 0.49
RXRG P48443 1/20 0.49
SLC40A1 Q9NP59 1/20 0.47
MRGPRX1 Q96LB2 1/20 0.44
RAD52 P43351 1/20 0.44
ALPL P05186 3/20 0.43
HDAC3 O15379 2/20 0.43
NCOR2 Q9Y618 2/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC2 Q92769 1/20 0.43
PTGER1 P34995 1/20 0.42
PTGER4 P35408 1/20 0.42
PTGER3 P43115 1/20 0.42
PTGER2 P43116 1/20 0.42
KCNA5 P22460 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3559725 0.95 SLC16A3 (0.58) SLC16A3RXRARXRBRXRGSLC40A1
SCHEMBL3563150 0.89 SLC16A3 (0.68) SLC16A3SLC40A1MRGPRX1RAD52ALPL
SCHEMBL3556453 0.87 RXRA (0.53) SLC16A3RXRARXRBRXRGALPL
SCHEMBL3554971 0.86 MEN1 (0.51) SLC16A3SLC40A1MRGPRX1RAD52ALPL
SCHEMBL3555732 0.84 SLC16A3 (0.62) SLC16A3SLC40A1MRGPRX1RAD52ALPL
SCHEMBL3553632 0.84 SLC16A3 (0.68) SLC16A3SLC40A1MEN1KMT2A
SCHEMBL3558244 0.83 SLC16A3 (0.67) SLC16A3HDAC3NCOR2HDAC1HDAC2
SCHEMBL3551918 0.83 MEN1 (0.50) SLC16A3SLC40A1MRGPRX1RAD52ALPL
SCHEMBL3555296 0.82 IDH1 (0.51) SLC16A3RXRARXRBRXRGALPL
SCHEMBL3553224 0.82 SLC16A3 (0.72) SLC16A3HDAC3NCOR2HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7816397-B2 Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2010-10-19 US claimed
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes MERCK PATENT GMBH (DE) 2008-02-21 US claimed
US-7816397-B2 Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2010-10-19 US disclosed
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes MERCK PATENT GMBH (DE) 2008-02-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes SLC5A1, ALDH7A1, ASS1 SLC16A3 425/4885RXRA 1293/4885RXRB 1002/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.